Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Leiden

406 clinical trials in Leiden, The Netherlands across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Leiden at a glance
406
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

406 trials in Leiden

Open in trial search

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Eyelid ptosis

Recruiting

Study on the Effectiveness and Safety of Oxymetazoline Hydrochloride Eye Drops for Adults with Acquired Blepharoptosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxymetazoline Hydrochloride
  • Sponsor:Santen

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Herpes zoster

Recruiting

Non‑inferiority of fractional varicella zoster virus glycoprotein E vaccine (AS01B) versus recombinant varicella zoster virus glycoprotein E vaccine in adults with shingles

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Leiden University Medical Center

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Epilepsy

Recruiting

Phase 2 Study Evaluating OV329 on Photo‑Induced EEG Response in Adults with Epilepsy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

Infectious pleural effusion

Recruiting

Intrapleural Alteplase and Dornase Alfa versus VATS for Patients with Pleural Empyema (Parapneumonic Pleural Infection)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Amsterdam UMC Stichting

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Huntington's disease

Recruiting

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Recruiting

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Leiden

What the registry says about research in the country

01 Infectious Diseases Research

Innovative studies focusing on viral infections including trials evaluating vaccines against yellow fever, influenza, and mpox. Research includes assessment of antibody responses and vaccine effectiveness in different populations.

  • Influenza vaccine efficacy in elderly
  • Yellow fever prophylaxis
  • Mpox booster vaccination

Particular emphasis on preventive strategies and immune response evaluation.

02 Neurological Studies

Comprehensive research targeting neurological conditions, including investigations into Parkinson's disease treatments and neural response patterns. Studies examine innovative therapeutic approaches.

  • Parkinson's Disease treatments
  • CNS response analysis
  • Cerebral Amyloid Angiopathy

Focus on developing targeted therapies and understanding brain mechanisms.

03 Cancer and Chronic Conditions

Advanced research in oncology and chronic diseases, including studies on gastric cancer imaging and T-cell lymphoma treatments. Investigations into kidney disease management.

  • Advanced solid tumors
  • Gastric cancer diagnosis
  • Chronic kidney disease

Emphasis on innovative diagnostic techniques and treatment approaches.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.